Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silence Therapeutics plcSLN · Entity 5028 | 10% owner | August 10, 2026 | August 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silence Therapeutics plc
Report date August 10, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 7,488,660 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Sale · Acquired 2,792,826 · Balance 7,488,660 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $15.58 | IndirectSee footnote | 7,388,660 |
Reported balance
After 2026-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-10 · Sale · Acquired 100,000 · Balance 7,388,660 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.09 | IndirectSee footnote | 7,338,660 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Sale · Acquired 50,000 · Balance 7,338,660 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.35 | IndirectSee footnote | 7,335,160 |
Reported balance
After 2026-08-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-10 · Sale · Acquired 3,500 · Balance 7,335,160 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 6,535,160 |
Reported balance
After 2026-08-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-10 · Sale · Acquired 800,000 · Balance 6,535,160 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 6,153,160 |
Reported balance
After 2026-08-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-10 · Sale · Acquired 382,000 · Balance 6,153,160 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.09 | IndirectSee footnote | 5,682,340 |
Reported balance
After 2026-08-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-10 · Sale · Acquired 470,820 · Balance 5,682,340 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 5,077,166 |
Reported balance
After 2026-08-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-10 · Sale · Acquired 605,174 · Balance 5,077,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 4,957,166 |
Reported balance
After 2026-08-10 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-10 · Sale · Acquired 120,000 · Balance 4,957,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.35 | IndirectSee footnote | 4,897,166 |
Reported balance
After 2026-08-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-08-10 · Sale · Acquired 60,000 · Balance 4,897,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
| American Depositary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $16.00 | IndirectSee footnote | 4,797,166 |
Reported balance
After 2026-08-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-08-10 · Sale · Acquired 100,000 · Balance 4,797,166 F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.
F2: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 11 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,797,166 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 60,000 | Not disclosed Strike: $16.35 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 10 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,897,166 Underlying: Ordinary Shares · 180,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 120,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 9 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,957,166 Underlying: Ordinary Shares · 360,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 605,174 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 8 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,077,166 Underlying: Ordinary Shares · 1,815,522 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 470,820 | Not disclosed Strike: $16.09 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 7 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,682,340 Underlying: Ordinary Shares · 1,412,460 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 382,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 6 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,153,160 Underlying: Ordinary Shares · 1,146,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 800,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 5 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,535,160 Underlying: Ordinary Shares · 2,400,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 3,500 | Not disclosed Strike: $16.35 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 4 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,335,160 Underlying: Ordinary Shares · 10,500 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $16.09 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,338,660 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 100,000 | Not disclosed Strike: $15.58 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,388,660 Underlying: Ordinary Shares · 300,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 10, 2026 Filed Aug 13, 2026 14:07 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 2,792,826 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001104659-26-095574 · tm2623118-2_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,488,660 Underlying: Ordinary Shares · 8,378,478 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL"), Blake Holdings Limited ("BHL"), Ora Ventures Limited ("OVL"), Ora Capital Limited ("OCL), Sarossa Plc ("SAR"), Pinkeys Limited ("PKL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL, BHL, OVL and OCL and the controlling shareholder of SAR and PKL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 06, 2026 Filed Jul 7, 2026 13:09 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 865,112 | Not disclosed Strike: $10.53 | Not disclosed |
DisclosureSEC source: 0001104659-26-080997 · tm2619820-1_4seq1.xml · derivative · entry 6 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 10,281,486 Underlying: Ordinary Shares · 2,595,336 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 13:09 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 50,082 | Not disclosed Strike: $10.47 | Not disclosed |
DisclosureSEC source: 0001104659-26-080997 · tm2619820-1_4seq1.xml · derivative · entry 5 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,146,598 Underlying: Ordinary Shares · 150,246 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 13:09 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $10.62 | Not disclosed |
DisclosureSEC source: 0001104659-26-080997 · tm2619820-1_4seq1.xml · derivative · entry 4 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,196,680 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 13:09 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 79,180 | Not disclosed Strike: $10.62 | Not disclosed |
DisclosureSEC source: 0001104659-26-080997 · tm2619820-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,246,680 Underlying: Ordinary Shares · 237,540 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 30, 2026 Filed Jul 7, 2026 13:09 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 169,928 | Not disclosed Strike: $10.76 | Not disclosed |
DisclosureSEC source: 0001104659-26-080997 · tm2619820-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,325,860 Underlying: Ordinary Shares · 509,784 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| June 29, 2026 Filed Jul 7, 2026 13:09 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 330,072 | Not disclosed Strike: $10.69 | Not disclosed |
DisclosureSEC source: 0001104659-26-080997 · tm2619820-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,495,788 Underlying: Ordinary Shares · 990,216 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Cream Capital Limited ("CCL") and Mr. Griffiths personally. Mr Griffiths is a director and the controlling shareholder of CCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| October 27, 2025 Filed Feb 13, 2026 11:02 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 2,000 | Not disclosed Strike: $7.75 | Not disclosed |
DisclosureSEC source: 0001104659-26-014603 · tm266179-1_4seq1.xml · derivative · entry 4 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,825,861 Underlying: Ordinary Shares · 6,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Ora Capital Limited ("OCL") and purchased by Mr. Griffiths personally, essentially internal transfers with no change in total beneficial holding. Mr Griffiths is a director and the controlling shareholder of OCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| October 27, 2025 Filed Feb 13, 2026 11:02 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 2,000 | Not disclosed Strike: $7.75 | Not disclosed |
DisclosureSEC source: 0001104659-26-014603 · tm266179-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,819,861 Underlying: Ordinary Shares · 6,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Ora Capital Limited ("OCL") and purchased by Mr. Griffiths personally, essentially internal transfers with no change in total beneficial holding. Mr Griffiths is a director and the controlling shareholder of OCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 03, 2025 Filed Feb 13, 2026 11:02 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 20,000 | Not disclosed Strike: $5.45 | Not disclosed |
DisclosureSEC source: 0001104659-26-014603 · tm266179-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,825,861 Underlying: Ordinary Shares · 60,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Ora Capital Limited ("OCL") and purchased by Mr. Griffiths personally, essentially internal transfers with no change in total beneficial holding. Mr Griffiths is a director and the controlling shareholder of OCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 03, 2025 Filed Feb 13, 2026 11:02 UTC | Silence Therapeutics plc SLN · Entity 5028 | SaleAmerican Depositary Shares · Derivative | 20,000 | Not disclosed Strike: $5.45 | Not disclosed |
DisclosureSEC source: 0001104659-26-014603 · tm266179-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,805,861 Underlying: Ordinary Shares · 60,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities were sold by Ora Capital Limited ("OCL") and purchased by Mr. Griffiths personally, essentially internal transfers with no change in total beneficial holding. Mr Griffiths is a director and the controlling shareholder of OCL. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| August 01, 2025 Filed Aug 4, 2025 12:03 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 4,034 | Not disclosed Strike: $6.14 | Not disclosed |
DisclosureSEC source: 0001104659-25-073386 · tm2522470-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,825,861 Underlying: Ordinary Shares · 12,102 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 12:03 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 14,342 | Not disclosed Strike: $6.18 | Not disclosed |
DisclosureSEC source: 0001104659-25-073386 · tm2522470-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,821,827 Underlying: Ordinary Shares · 43,026 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 30, 2025 Filed Jul 31, 2025 12:43 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 8,923 | Not disclosed Strike: $6.14 | Not disclosed |
DisclosureSEC source: 0001104659-25-072499 · tm2522205-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,807,485 Underlying: Ordinary Shares · 26,769 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 12:43 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 14,559 | Not disclosed Strike: $6.20 | Not disclosed |
DisclosureSEC source: 0001104659-25-072499 · tm2522205-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,798,562 Underlying: Ordinary Shares · 43,667 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 22, 2025 Filed Jul 23, 2025 18:22 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 2,910 | Not disclosed Strike: $6.09 | Not disclosed |
DisclosureSEC source: 0001104659-25-069944 · tm2521554-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,784,003 Underlying: Ordinary Shares · 8,730 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 18:22 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 22,435 | Not disclosed Strike: $6.04 | Not disclosed |
DisclosureSEC source: 0001104659-25-069944 · tm2521554-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,781,093 Underlying: Ordinary Shares · 67,305 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr. Griffiths is a director and the controlling shareholder of Cream. Mr. Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 18:58 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 43,293 | Not disclosed Strike: $6.40 | Not disclosed |
DisclosureSEC source: 0001104659-25-068309 · tm2521080-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 11,758,658 Underlying: Ordinary Shares · 129,879 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F2 · ownership.nature: The securities are held by Cream Capital Limited ("Cream"). Mr Griffiths is a director and the controlling shareholder of Cream. Mr Griffiths disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein. Read SEC document |
| July 11, 2025 Filed Jul 16, 2025 18:58 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 28,000 | Not disclosed Strike: $6.43 | Not disclosed |
DisclosureSEC source: 0001104659-25-068309 · tm2521080-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,715,365 Underlying: Ordinary Shares · 84,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 12:36 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 30,133 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001104659-25-066857 · tm2520411-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,687,365 Underlying: Ordinary Shares · 90,399 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| July 08, 2025 Filed Jul 10, 2025 12:36 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 24,387 | Not disclosed Strike: $5.94 | Not disclosed |
DisclosureSEC source: 0001104659-25-066857 · tm2520411-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,657,232 Underlying: Ordinary Shares · 73,161 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| July 07, 2025 Filed Jul 10, 2025 12:36 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 7,937 | Not disclosed Strike: $5.65 | Not disclosed |
DisclosureSEC source: 0001104659-25-066857 · tm2520411-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,632,845 Underlying: Ordinary Shares · 23,811 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 27, 2025 Filed Jun 30, 2025 16:31 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 24,000 | Not disclosed Strike: $5.82 | Not disclosed |
DisclosureSEC source: 0001104659-25-063969 · tm2519448-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,624,908 Underlying: Ordinary Shares · 72,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 16:31 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 20,735 | Not disclosed Strike: $5.67 | Not disclosed |
DisclosureSEC source: 0001104659-25-063969 · tm2519448-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,600,908 Underlying: Ordinary Shares · 62,205 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 16:31 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 65,739 | Not disclosed Strike: $5.91 | Not disclosed |
DisclosureSEC source: 0001104659-25-063969 · tm2519448-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,580,173 Underlying: Ordinary Shares · 197,217 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 12:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 26,624 | Not disclosed Strike: $6.12 | Not disclosed |
DisclosureSEC source: 0001104659-25-062407 · tm2518943-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,514,434 Underlying: Ordinary Shares · 79,872 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 12:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 35,005 | Not disclosed Strike: $5.88 | Not disclosed |
DisclosureSEC source: 0001104659-25-062407 · tm2518943-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,487,810 Underlying: Ordinary Shares · 105,015 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 22, 2025 Filed Jun 25, 2025 12:59 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 20,977 | Not disclosed Strike: $5.84 | Not disclosed |
DisclosureSEC source: 0001104659-25-062407 · tm2518943-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,452,805 Underlying: Ordinary Shares · 62,931 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 10:46 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 39,049 | Not disclosed Strike: $5.69 | Not disclosed |
DisclosureSEC source: 0001104659-25-060862 · tm2518525-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,431,828 Underlying: Ordinary Shares · 117,147 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 10:46 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 31,399 | Not disclosed Strike: $5.29 | Not disclosed |
DisclosureSEC source: 0001104659-25-060862 · tm2518525-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,392,779 Underlying: Ordinary Shares · 94,197 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 12:06 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 39,305 | Not disclosed Strike: $5.15 | Not disclosed |
DisclosureSEC source: 0001104659-25-059168 · tm2517968-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,361,380 Underlying: Ordinary Shares · 117,915 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 28, 2025 Filed May 29, 2025 15:21 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 9,169 | Not disclosed Strike: $5.11 | Not disclosed |
DisclosureSEC source: 0001104659-25-054045 · tm2516482-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,322,075 Underlying: Ordinary Shares · 27,507 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 27, 2025 Filed May 29, 2025 15:21 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 50,000 | Not disclosed Strike: $5.13 | Not disclosed |
DisclosureSEC source: 0001104659-25-054045 · tm2516482-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,312,906 Underlying: Ordinary Shares · 150,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 26, 2025 Filed May 29, 2025 15:21 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 26,669 | Not disclosed Strike: $4.91 | Not disclosed |
DisclosureSEC source: 0001104659-25-054045 · tm2516482-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,262,906 Underlying: Ordinary Shares · 80,007 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 23, 2025 Filed May 27, 2025 12:35 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 17,187 | Not disclosed Strike: $4.92 | Not disclosed |
DisclosureSEC source: 0001104659-25-052749 · tm2516192-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,236,237 Underlying: Ordinary Shares · 51,561 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 22, 2025 Filed May 27, 2025 12:35 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 19,174 | Not disclosed Strike: $5.04 | Not disclosed |
DisclosureSEC source: 0001104659-25-052749 · tm2516192-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,219,050 Underlying: Ordinary Shares · 57,522 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 20, 2025 Filed May 21, 2025 10:49 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 16,000 | Not disclosed Strike: $4.07 | Not disclosed |
DisclosureSEC source: 0001104659-25-051284 · tm2515795-1_4seq1.xml · derivative · entry 3 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,199,876 Underlying: Ordinary Shares · 48,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 19, 2025 Filed May 21, 2025 10:49 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 26,000 | Not disclosed Strike: $4.07 | Not disclosed |
DisclosureSEC source: 0001104659-25-051284 · tm2515795-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,183,876 Underlying: Ordinary Shares · 78,000 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 18, 2025 Filed May 21, 2025 10:49 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 37,023 | Not disclosed Strike: $4.01 | Not disclosed |
DisclosureSEC source: 0001104659-25-051284 · tm2515795-1_4seq1.xml · derivative · entry 1 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,157,876 Underlying: Ordinary Shares · 111,069 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:51 UTC | Silence Therapeutics plc SLN · Entity 5028 | PurchaseAmerican Depositary Shares · Derivative | 55,766 | Not disclosed Strike: $4.07 | Not disclosed |
DisclosureSEC source: 0001104659-25-049572 · tm2515252-1_4seq1.xml · derivative · entry 2 Griffiths Richard Ian · CIK 0001846370 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,120,853 Underlying: Ordinary Shares · 167,298 shares Expires not disclosed F1 · price: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.exercise_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. F1 · derivative.expiration_date: Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.